TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: AARTIPHARM · data 2026-11-02
Aarti Pharmalabs Limited
In plain words
Price: 11.4% below its 52-week high of ₹1,002.4.
Delivery: 44.1% of traded shares were kept for delivery over the last 10 sessions, against 41.4% over the last 60.
Latest results: a net profit of ₹46 cr for the quarter ended Dec 2025 (-37.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹2,161 cr |
| Net profit (last 12 months) | ₹257 cr |
| Sales growth, 3 years (yearly) | -2.6% |
| Profit growth, 3 years (yearly) | -3.3% |
At a glance
Promoters 42.9%, pledged 11.1%, institutions 15.4%.
P/E 31.4, P/B 3.6, dividend yield 0.4%. Price relative to earnings and book value (low is cheaper, not better).
ROE 8.5%, ROCE 11.5%, operating margin 17.7%: how much profit it earns on the money it uses.
Debt/equity 0.36, Profit growth -3.3% and sales growth -2.6% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Profit fell 3.3% a year over 3 years.
- Promoters have pledged 11.1% of their shares.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q3 FY26)
AARTIPHARM Q3 FY26 results (consolidated figures, as filed on NSE).
Revenue was ₹432.27 crore, down 19.6% YoY and up 3.3% QoQ.
Net profit was ₹46.39 crore, down 37.3% YoY and up 62.4% QoQ.
Operating margin was 23.7% (23.9% a year ago).
EPS was ₹5.29, down 35.2% YoY and up 71.8% QoQ.
AARTIPHARM के Q3 FY26 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹432.27 करोड़; पिछले साल की तुलना में 19.6% की गिरावट, पिछली तिमाही की तुलना में 3.3% की बढ़त।
शुद्ध मुनाफ़ा: ₹46.39 करोड़; पिछले साल की तुलना में 37.3% की गिरावट, पिछली तिमाही की तुलना में 62.4% की बढ़त।
ऑपरेटिंग मार्जिन: 23.7% (एक साल पहले 23.9%)।
EPS: ₹5.29; पिछले साल की तुलना में 35.2% की गिरावट, पिछली तिमाही की तुलना में 71.8% की बढ़त।
AARTIPHARMના Q3 FY26 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹432.27 કરોડ; ગયા વર્ષની સરખામણીએ 19.6% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 3.3% વધારો.
ચોખ્ખો નફો: ₹46.39 કરોડ; ગયા વર્ષની સરખામણીએ 37.3% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 62.4% વધારો.
ઓપરેટિંગ માર્જિન: 23.7% (એક વર્ષ પહેલાં 23.9%).
EPS: ₹5.29; ગયા વર્ષની સરખામણીએ 35.2% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 71.8% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
23/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 10/30: Delivery 37.8% over the last 20 sessions vs 27.9% in the 40 before (1.35x); shares delivered per day 0.82x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 8/20: Net +₹23.57 cr bought in bulk/block deals over 90 days (0.39x a usual day's traded value); 1 net buying day, 1 net selling day.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Deal ● Dividend ● Results
- 21 Sept 26Deal Bulk deal: UNIFI CAPITAL PRIVATE LIMITED bought ₹75.03 cr +7.7% next session
- 18 Sept 26Deal Bulk deal: JASMINE FAMILY TRUST sold ₹51.46 cr +2.4% next session
- 15 Sept 26Dividend Dividend ₹2 (ex-date) -1.7% next session
- 7 Aug 26Results Results board meeting +18.9% next session
- 25 May 26Results Results board meeting -2.6% next session
- 18 May 26Results Results board meeting -0.8% next session
- 16 Feb 26Dividend Dividend ₹1.5 (ex-date) +2.0% next session
- 9 Feb 26Results Q3 FY26 results: profit −37.3% YoY -1.6% next session
- 9 Nov 25Results Q2 FY26 results: net profit ₹28.6 cr -11.4% next session
- 15 Sept 25Dividend Dividend ₹2.5 (ex-date) -1.5% next session
- 12 Aug 25Results Results board meeting -8.0% next session
- 10 May 25Results Results board meeting +4.4% next session
- 14 Feb 25Dividend Dividend ₹2.5 (ex-date) +7.4% next session
- 6 Feb 25Results Q3 FY25 results: net profit ₹74 cr +16.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Dec 2025 | ₹432 cr | ₹46 cr | -37.3% | 23.7% | 5.29 |
| Sept 2025 | ₹418 cr | ₹29 cr | — | 17.9% | 3.08 |
| Dec 2024 | ₹538 cr | ₹74 cr | — | 23.9% | 8.16 |
Shareholding trend
| Holder | Jun 2026 |
|---|---|
| Promoters | 42.86% |
| Foreign institutions (FII) | 8.17% |
| Domestic institutions (DII) | 7.22% |
| Mutual funds | 0.79% |
| Retail investors | 23.95% |
| Number of shareholders | 1,76,506 |
Common questions
What was Aarti Pharmalabs Limited's latest quarterly profit?
Aarti Pharmalabs Limited reported a net profit of ₹46 cr for the quarter ended Dec 2025 (-37.3% on the same quarter a year earlier), on revenue of ₹432 cr.
How much do promoters hold in Aarti Pharmalabs Limited?
Promoters held 42.86% of Aarti Pharmalabs Limited at the end of Jun 2026, with 11.08% of promoter shares pledged.
Is Aarti Pharmalabs Limited debt-free?
Its latest reported debt-to-equity ratio is 0.36.
What is Aarti Pharmalabs Limited's P/E ratio?
About 31.4, based on the last 12 months' earnings and a price of ₹887.95 (data 2026-11-02).
What is the 52-week high and low of Aarti Pharmalabs Limited?
The 52-week high is ₹1,002.4 and the 52-week low is ₹585.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Aarti Pharmalabs Limited | ₹887.95 | ₹7,922 cr | 31.4 | 3.6 | 8.5% | 11.5% | 0.36 | +6.2% |
| Symbiotec Pharmalab Limited | ₹1,237.9 | ₹8,001 cr | — | — | — | — | — | +25.3% |
| Sanofi Consumer Healthcare India Limited | ₹3,497.5 | ₹7,911 cr | 28.8 | — | 73.1% | 82.8% | 0.06 | -24.8% |
| Sanofi India Limited | ₹3,289.3 | ₹7,380 cr | 20.8 | — | 40.6% | 54.6% | 0.02 | -31.5% |
| Suven Life Sciences Limited | ₹262.15 | ₹7,293 cr | — | — | -78.8% | -80.8% | 0.03 | +35.2% |
| Bliss GVS Pharma Limited | ₹626 | ₹6,894 cr | 49.6 | — | 11.5% | 10.9% | 0.02 | +300.8% |
Compare AARTIPHARM with SYMBIOTEC in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open AARTIPHARM in TickerKhoj →